Description
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 23 bp deletion in exon3 and 71 bp insertion in exon3.,
Disease:Adenocarcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-ECHDC1, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
ECHDC1 also known as 'enoyl-CoA hydratase domain-containing protein 1' plays a role in fatty acid metabolism through its enzymatic activity. It weighs around 39 kDa and can be found in various tissues but it has higher expression levels in the heart and muscle tissues. This protein participates in metabolic processes by catalyzing the hydration of enoyl-CoA during the beta-oxidation of fatty acids.
Biological function summary
EVT-888 (another name for ECHDC1 used in some studies) acts as a component that affects metabolic pathways by mediating reactions associated with energy production. Though it is not actively considered formally as a part of large enzyme complexes ECHDC1 indirectly relates to mitochondrial function and energy regulation. It influences long-chain fatty acid breakdown assisting cells to maintain energy homeostasis.
Pathways
ECHDC1 influences key metabolic pathways like the beta-oxidation pathway of fatty acids and the mitochondrial respiration chain. This protein interacts closely with other proteins such as ACADVL (very long-chain specific acyl-CoA dehydrogenase) and HADHA (hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha) playing a central role in energy conversion and mitochondrial efficiency.
Alterations in ECHDC1 expression or function may associate with metabolic syndromes and cardiomyopathies due to its involvement in fatty acid metabolism and energy production. Disrupted interactions with metabolic proteins like HADHA and ACADVL can result in energy production deficits linking ECHDC1 to inherited metabolic disorders related to mitochondrial anomalies.
